Art

J-GLOBAL ID：201902244741258001   Reference number：19A0715095

Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib

セリバニブ治療に関連する肝胆道有害作用の病理学におけるインターロイキン18の関与の可能性【JST・京大機械翻訳】

Author (6)： Hirano Taizou (Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan) ,  koarai Akira (Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan) ,  Ichikawa Tomohiro (Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan) ,  Sato Teruyuki (Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan) ,  Ohe Takashi (Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan) ,  Ichinose Masakazu (Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan)
Material： BMC Cancer (Web)
Volume： 18  Issue： 1  Page： 995  Publication year： 2018 
JST Material Number： U7305A  ISSN： 1471-2407  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Abstract/Point： Ceritinib demonstrated a stati...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0715095&from=J-GLOBAL&jstjournalNo=U7305A") }}

Thesaurus term： *interleukin ,  case report ,  phase 3 study ,  bile duct ,  *pathological state ,  antibody ,  serum ,  inflammation ,  enzyme ,  side effect ,  human(primates) ,  non-small cell lung cancer ,  drug therapy ,  woman ,  toxicity ,  image

Author keywords (4)： Lung cancer ,  Ceritinib ,  Drug induced hepatobiliary adverse events ,  Interleukin 18

JST classification (2)： Gene expression  (EC02040Q) ,  Chemistry,biochemistry and pathology of tumors(=neoplasms)  (GE02030N)

Reference (13)：

• Lancet; First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomized, open-label, phase 3 study; JC Soria, DS Tan, R Chiari; 389; 10072; 2017; 917-929; 10.1016/S0140-6736(17)30123-X; citation_id=CR1
• Lancet Oncol; Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicenter, open-label, phase 1 trial; DW Kim, R Mehra, DS Tan; 17; 4; 2016; 452-463; 10.1016/S1470-2045(15)00614-2; citation_id=CR2
• J Clin Oncol; Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2; L Crinò, MJ Ahn, F De Marinis; 34; 24; 2016; 2866-2873; 10.1200/JCO.2015.65.5936; citation_id=CR3
• Felip E, Orlov S, Park K, et al. Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): whole body responses in the overall pts group and in pts with baseline brain metastases (BM). Ann Oncol. 2016;27(6) Meeting Abstract: 1208O.https://academic.oup.com/annonc/article/27/suppl_6/1208O/2800066.
• Lancet Oncol; ASCEND-5: a randomized, phase3 study of ceritinib versus chemotherapy in adult patients with ALK-rearranged non-small cell lung cancer, previously treated with chemotherapy and crizotinib; AT Shaw, TM Kim, L Crinò; 18; 7; 2017; 874-886; 10.1016/S1470-2045(17)30339-X; citation_id=CR5

Terms in the title (6)： 治療 ,  胆道 ,  有害作用 ,  病理学 ,  インターロイキン18 ,  可能性